Most people with COVID-19 will be able to manage symptoms and recover at home.

COVID-19 treatments are available for people who are at higher risk of severe disease and health outcomes. This includes people who are not fully vaccinated, have a low immune system or suffer from a chronic condition such as diabetes

These treatments will not be suitable for everyone and are prescription only. If required, your health care provider will work with you to determine which treatment option is suitable for your circumstances.

If you think you may be eligible to receive one of these treatments, discuss this with your usual GP or health care provider, who can refer you either to a COVID Care Centre or provide a script for anti-viral tablets.

Eligibility to COVID-19 treatments

People who are at higher risk of severe disease from COVID-19 may be eligible for COVID-19 treatments.

This includes people who are not up-to-date (less than 3 doses) with their COVID-19 vaccines and have one or more of the identified risk factors for COVID-19, or who have a low immune system.

Risk factors include:

  • aged 60 years or older
  • Aboriginal or Torres Strait Islander aged 50 years or older
  • obesity
  • active cancer
  • chronic kidney disease
  • chronic liver disease
  • chronic lung disease
  • serious heart conditions
  • sickle cell disease
  • neurodevelopmental disorders (e.g. cerebral palsy, Downs syndrome)
  • diabetes
  • immunocompromising conditions or on immunosuppressive therapy.

Monitor your COVID-19 symptoms and determine your eligibility for COVID-19 treatments using the healthdirect symptom checker.

Oral treatments for COVID-19

The Therapeutic Goods Administration (TGA) has granted provisional approval to two oral COVID-19 treatments:

  • Paxlovid (nirmatrelvir + ritonavir)
  • Lagevrio (molnupiravir)

These oral treatments have been found to be effective in treating mild to moderate COVID-19 in adults who are at a higher risk of severe outcomes from COVID-19. These treatments aim to help reduce your risk of hospitalisation.

People can access the treatment in their own home or supported living setting without needing to travel to a hospital.

Lagevrio (molnupiravir) can now be prescribed by a GP and accessed through the Pharmaceutical Benefit Scheme, which requires a script to be sent to the pharmacy.

More information on medications for treating COVID-19 is available on the healthdirect website.

Health care providers can find more information on treatments and referrals for mild COVID-19 illness on the SA Health website.

Infusion treatments for COVID-19

The TGA has granted provisional approval for sotrovimab infusion treatment to be used in Australia.

People with confirmed COVID-19 who are at high risk of COVID-19 can be referred by a health care provider to access an infusion.

The treatment requires a single dose to be administered through an intravenous infusion in a health care facility and reduces the risk of severe illness and hospitalisation.

More information on medications for treating COVID-19 is available on the healthdirect website.

Health care providers can find more information on treatments and referrals for mild COVID-19 illness on the SA Health website.